Press releases

17 December 2021
Subscription to raise £1.63m to progress SDC-1801

16 December 2021
Result of AGM

16 December 2021
AGM Statement

15 December 2021
Intention to Grant Notice - EU Patent for SDC-1802

07 December 2021
AGM Update

23 November 2021
Director/PDMR Shareholding

19 November 2021
Notice of AGM

03 November 2021
Exercise of Share Options and Director Dealings

29 October 2021
Appointment of Joint Corporate Broker

25 October 2021
Final Results

21 October 2021
Notice of Results

07 October 2021
US Patent Granted for SDC-1802 TYK2/JAK1 Inhibitor

29 September 2021
Reference to SRA737 Timeline at Cantor Conference

19 August 2021
Trading Statement

09 August 2021
Subscription to raise GBP 1,000,000

06 August 2021
SRA737 Update

30 July 2021
Patent Notice of Allowance for SDC-1802

19 July 2021
Subscription to raise £1,000,000

14 July 2021
Exercise of Warrants and Total Voting Rights

01 July 2021
Completed Covid-19 Research Project Delivers Encouraging Results

21 June 2021
Sareum to Present at BioTrinity 2021 Conference

15 June 2021
Subscription to raise £1,470,000

01 June 2021
Subscription to Raise £900,000

25 May 2021
Trading Update

13 May 2021
Exercise of Options and TVR

23 April 2021
Half-year Report

25 March 2021
Research Update

25 March 2021
Interim Results Extension

16 February 2021
Sareum Notes New UK Government Covid-19 Initiative

01 February 2021
Sareum to Present at the LSX World Congress 2021

26 January 2021
Sareum to Participate in the Edison Open House

08 January 2021
Update re: FLT3+Aurora Kinase Inhibitor Programme

07 January 2021
US Patent Grant for TYK2/JAK1 Anticancer Candidate

17 December 2019
Result of AGM

17 December 2019
AGM Statement

20 November 2019
Notice of AGM

05 November 2019
Sareum notes Sierra Oncology Q3 2019 Results

30 October 2019
Research Update - SDC-1802 Anti-Cancer Poster

17 October 2019
Research Update - AACR-NCI-EORTC abstract

15 October 2019
Final Results for the Year Ended 30 June 2019

07 October 2019
Notice of Full Year Results

27 September 2019
Research Update - TYK2/JAK1 Cancer Programme

27 August 2019
Trading Statement

16 August 2019
Change of Adviser

08 August 2019
Sareum notes Sierra Q2 results

30 July 2019
Additional disclosure concerning Michael Owen

28 June 2019
Additional Funds Raised

27 June 2019
Sierra Seeks Strategic Options for SRA737

26 June 2019
Successful Fundraising

25 June 2019
PrimaryBid.com Offer

25 June 2019
Placing to Progress TYK2/JAK1 Programmes

13 June 2019
Portfolio Update

03 June 2019
Key Takeaways from SRA737 Webcast at ASCO

03 June 2019
Positive SRA737 Data Reported at ASCO

16 May 2019
ASCO Abstracts for SRA737 Published

08 May 2019
Sareum notes Sierra Oncology Q1 2019 Results

30 April 2019
Sareum to Present at BioTrinity 2019 in London

23 April 2019
SRA737 Phase I/IIa data to be presented at ASCO

02 April 2019
Preclinical Data for SRA737 Presented at AACR 2019

12 March 2019
Issue of Options

04 March 2019
Half Yearly Results Ended 31 Dec 2018

28 February 2019
Sierra Oncology has reported its 2018 results

28 February 2019
New SRA737 preclin data to be presented at AACR

23 January 2019
Sierra Oncology to present SRA737 at DDR Tx Summit

15 December 2015
Result of AGM

15 December 2015
CHK1 Clinical Trial Applications

13 November 2015
Notice of AGM

26 October 2015
Final Results

15 September 2015
US and European Patent Grants for Aurora+FLT3

23 July 2015
CHK1 Research Update

First description of the CHK1 clinical development candidate published in peer-reviewed journal: New ‘chemotherapy booster’ could treat lung and pancreatic cancer

17 June 2015
FUNDING AWARD FROM INNOVATE UK

Award of up to £140,000 to investigate the potential of TYK2 inhibitors to treat adolescent leukaemia

28 May 2015
Placing

21 May 2015
Sareum Launches New Website

12 May 2015
Sareum to Present at BioTrinity 2015

07 May 2015
Early Conclusion of Equity Swap Agreement

16 March 2015
Change of Adviser

25 February 2015
Research & Co-Development Collaborations Update

25 February 2015
Half-yearly Report

20 January 2015
Further US Patent Grant for Sareum’s Kinase Inhibitors